Unicycive Therapeutics, Inc. Board of Directors

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Dr. Shalabh K. Gupta M.D., MPA

Dr. Shalabh K. Gupta M.D., MPA

Founder, Chairman, CEO & President

Dr. Pramod Gupta Ph.D.

Dr. Pramod Gupta Ph.D.

Executive Vice President of Pharmaceutical & Business Operations

Mr. Douglas Jermasek M.B.A.

Mr. Douglas Jermasek M.B.A.

Executive Vice President of Corporate Strategy

Mr. John W. Townsend CPA

Mr. John W. Townsend CPA

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.